{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/mi-secondary-prevention/background-information/complications-prognosis/","result":{"pageContext":{"chapter":{"id":"b05c9d6f-fae2-5624-bc64-e5456fa46e84","slug":"complications-prognosis","fullItemName":"Complications and prognosis","depth":2,"htmlHeader":"<!-- begin field 85fdf326-ca6e-4303-991d-a78101263cd9 --><h2>Complications and prognosis</h2><!-- end field 85fdf326-ca6e-4303-991d-a78101263cd9 -->","summary":"","htmlStringContent":"<!-- begin item c887e84f-b243-4da4-8dee-a78101263b81 --><!-- end item c887e84f-b243-4da4-8dee-a78101263b81 -->","topic":{"id":"10808f6c-5a83-5526-84e2-5998dee92475","topicId":"0b3a22ee-885a-43aa-8d4b-a290dc2afbcc","topicName":"MI - secondary prevention","slug":"mi-secondary-prevention","lastRevised":"Last revised in May 2020","chapters":[{"id":"6d17bc7f-3ed1-5a79-b4f4-8e9dc752c658","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a57b961c-8bba-5c02-8844-b6307b89222c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"dc552ddd-7106-5f5f-a7d9-4b2d6f80e1fa","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e9a32a50-5bdc-5fc0-8ecb-152881ffa7ad","slug":"changes","fullItemName":"Changes"},{"id":"d4c6dcc6-12c6-52a1-957d-47a931a225ec","slug":"update","fullItemName":"Update"}]},{"id":"8c06d36f-1d73-5741-981b-5ed3cc16b7c2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cd13560d-8bec-5902-9a9e-2ce26eaa9028","slug":"goals","fullItemName":"Goals"},{"id":"b9d35945-0a30-523a-9ded-6a2ea7f5a79a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5c84a4ff-a034-50b3-b1a3-7cfecfb1e65c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"02b0b701-c0f0-542f-b958-8d30a81301fc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f516bbb5-ea19-5f8f-be12-d8f550493156","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cf211bbf-df50-54c9-b204-ef227db8c62f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3ddc8181-0420-5ae4-8326-2d5ef700203a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f303e07d-da7d-5073-b00b-f3dd008f2594","slug":"definition","fullItemName":"Definition"},{"id":"45810734-c13c-5bbd-b314-88dcbfd54c57","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5488a58d-1964-5d60-a54e-a420fd0daeff","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b05c9d6f-fae2-5624-bc64-e5456fa46e84","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"2dd1d8e3-398b-5765-b249-43150874e311","fullItemName":"Management","slug":"management","subChapters":[{"id":"6854ca49-f0af-50f1-8fd3-a6bb900b4bc4","slug":"secondary-prevention","fullItemName":"Scenario: Secondary prevention"}]},{"id":"a4fb09c9-df2a-5800-954a-58fe23af6127","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e43e8d70-7611-5939-94cb-7cc18a3950a6","slug":"ace-inhibitors","fullItemName":"ACE inhibitors"},{"id":"0220c0cb-0802-5bfa-9d8b-f767f73dbea1","slug":"antiplatelet-treatments","fullItemName":"Antiplatelet treatments"},{"id":"a6c13387-db91-5f87-9795-c95a1be0a245","slug":"beta-blockers","fullItemName":"Beta blockers"},{"id":"064bc21b-4d02-5987-9c23-08b1ca8870d1","slug":"statins","fullItemName":"Statins"}]},{"id":"05c20737-02bb-500e-b3e6-0a506d19e727","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1ae6e3bc-f751-5c4b-a14d-09c72b74424e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a3e487f8-13d0-532b-b16f-d448106af2ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"03c8dfe8-3b8b-5c16-ab71-21f98aa13dcd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a1919ef1-18db-59ab-8c6d-7ef4d649f5d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3e57d884-d476-55de-a85c-a5e4e2001343","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e8c5059d-6ccf-58a3-bb80-1a8273c64c14","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bcfd412e-e461-5a99-a38f-a03a01873fa5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3ddc8181-0420-5ae4-8326-2d5ef700203a","slug":"background-information","fullItemName":"Background information"},"subChapters":[{"id":"650eab3d-d836-5eb4-bbc4-e0f3cccf4452","slug":"complications","fullItemName":"Complications","depth":3,"htmlHeader":"<!-- begin field bd383c01-ab1d-4d96-a347-a7810126b9ad --><h3>Complications</h3><!-- end field bd383c01-ab1d-4d96-a347-a7810126b9ad -->","summary":null,"htmlStringContent":"<!-- begin item 7601c5ea-a54f-446a-80ea-a7810126b811 --><!-- begin field 086169f8-a86e-4553-a16a-a7810126b9ad --><ul><li><strong>Possible complications following a myocardial infarction (MI) include:</strong><ul><li><strong>Acute heart failure</strong>:<ul><li>Within hours after the MI — due to 'stunning' of the myocardium, an arrhythmia, or by an extensive volume of infarction.</li><li>In the days following the MI — due to rupture of a papillary muscle and resulting valvular incompetence, or by ventricular rupture resulting in a ventricular septal defect.</li><li>Anytime later — caused by acute decompensation of chronic heart failure, and in those with left ventricular systolic dysfunction.</li></ul></li><li><strong>Chronic heart failure</strong> — most commonly presents with breathlessness, fatigue, and oedema. For more information on the diagnosis and management of chronic heart failure, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>.</li><li><strong>Post-infarction angina</strong> — characterized by pain or heaviness in the centre of the chest triggered by effort or emotion. For information on the diagnosis and management of angina, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angina/\">Angina</a>.</li><li><strong>Stroke</strong> — People with coronary heart disease, or who have had an MI, are twice as likely to experience a stroke as people without these risk factors. For information on the diagnosis and management of stroke, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/stroke-tia/\">Stroke and TIA</a>.</li><li><strong>Depression</strong> — up to 20% of people have a major depressive episode following an MI and a further 25% experience minor depression or depressed mood [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Jiang et al, 2005</a>]. For information on the diagnosis and management of depression, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>.</li><li><strong>Anxiety disorders</strong> — are thought to be common post-MI and may contribute to poorer outcomes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Roest et al, 2010</a>]. One study found that 7% of people undergoing cardiac rehabilitation had an anxiety disorder [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Bunevicius et al, 2013</a>]. For information on the diagnosis and management of anxiety, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>.</li><li><strong>Dressler's syndrome</strong> — a pericarditis that occurs in about 4% of people post-MI. People typically present 2–4 weeks after an MI with a self-limiting febrile illness accompanied by pericardial or pleural pain [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Gibson, 2003</a>].</li><li><strong>Sudden death</strong> — can occur shortly after MI because of myocardial rupture or fatal arrhythmia, or may occur at any time because of re-infarction or arrhythmia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Steg et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Timmis, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">BHF, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">BMJ Best Practice, 2018</a>]</p><!-- end field 086169f8-a86e-4553-a16a-a7810126b9ad --><!-- end item 7601c5ea-a54f-446a-80ea-a7810126b811 -->","subChapters":[]},{"id":"90ba2034-6a33-596a-ba20-14cff2cf3491","slug":"prognosis","fullItemName":"Prognosis","depth":3,"htmlHeader":"<!-- begin field 65b1284a-fe8f-491c-823c-a7810126cbfc --><h3>Prognosis</h3><!-- end field 65b1284a-fe8f-491c-823c-a7810126cbfc -->","summary":null,"htmlStringContent":"<!-- begin item 910bc735-d494-4c77-9868-a7810126ca59 --><!-- begin field dba25f3e-585e-445b-85a4-a7810126cbfc --><ul><li><strong>The prognosis following a myocardial infarction (MI) has considerably improved in recent years.</strong> This is largely attributable to modern treatments, in particular percutaneous coronary interventions and secondary preventative measures. For example:<ul><li>The British Heart Foundation states that in the 1960s more than 70% of heart attacks in the UK were fatal, whereas today, at least 7 out of 10 people survive [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">BHF, 2018</a>].</li><li>A Swedish study followed up 61,238 people with a first ST-elevation MI (STEMI) between 1996 and 2007, over which time the use of modern treatments greatly increased. In-hospital, 30-day and 1-year mortality rates decreased from 12.5% to 7.2%; from 15.0% to 8.6%; and from 21.0% to 13.3% respectively [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Jernberg et al, 2011</a>].</li><li>In England and Wales, the Myocardial Ischaemia National Audit Project (MINAP) reported that the 30-day mortality was almost 13% for STEMI in 2003–4, falling to 8% in 2011–12, with similar falls for NSTEMI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">NICOR, 2013</a>].</li></ul></li><li><strong>Greater degrees of myocardial necrosis are associated with a worse prognosis</strong> <strong>and higher risk of heart failure</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Fox et al, 2004</a>]<strong>.</strong></li><li><strong>Other factors that may adversely affect prognosis</strong> <strong>following an MI include:</strong><ul><li>Comorbidities such as hypertension, chronic kidney disease, anaemia, and diabetes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Shu et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Stebbins et al, 2010</a>].</li><li>Site of the infarction. For example, a STEMI in the anterior part of heart has a less favourable prognosis than one in the inferior part of the heart [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Stebbins et al, 2010</a>].</li><li>Depression, particularly treatment-resistant and insufficiently treated depression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Licthman et al, 2014</a>].</li><li>Older age and female sex [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Stebbins et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">Canto et al, 2012</a>].</li></ul></li></ul><!-- end field dba25f3e-585e-445b-85a4-a7810126cbfc --><!-- end item 910bc735-d494-4c77-9868-a7810126ca59 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}